Abivax appoints Dr Sophie Biguenet as Chief Medical Officer

pharmafile | March 2, 2021 | Appointment | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing  

Clinical-stage biotechnology company Abivax has appointed Dr Sophie Biguenet as Chief Medical Officer.

Dr Biguenet brings 25 years of experience in academia and in the biopharmaceutical industry to the role, with an extensive track record in international clinical development, leading to the successful registration of several new drug products across various treatment areas.

Prior her position at Abivax, Dr Biguenet served as CMO at Versantis, a Swiss clinical-stage biotech company, where she successfully took the pipeline from pre-clinical to Phase IIb. She is a board-certified general and paediatric surgeon, and began her biopharmaceutical career focusing on immunosuppression in solid organ transplantation.

Before joining Versantis, she held leadership positions in global drug development at Biogen, Bristol-Myers Squibb, AbbVie, and the Medicines for Malaria Venture.

Dr Biguenet commented: “I am thrilled to join the Abivax team during these exciting times for the company and ahead of a number of important clinical decisions to be taken and implemented.

“With inflammatory bowel diseases being Abivax’s main area of focus, the initiation of two pivotal Phase III trials in ulcerative colitis and one pivotal Phase IIb/III trial in Crohn’s disease will lay the cornerstones for the late-stage development of [the company’s lead compound] ABX464.

“I am excited to drive the clinical progress of ABX464 to fully exploit its potential as a novel long-term therapy option addressing high unmet medical needs in the inflammatory disease field as well as in COVID-19.”

Related Content

No items found

Latest content